Adam Schayowitz Sells 13,832 Zymeworks Shares at $25.85 Each – Form 4 Filed on October 11, 2026

On October 11, 2026, Adam Schayowitz, EVP and Head of Research & Development at Zymeworks Inc. (ZYME), sold 13,832 shares at $25.85 each, for a total value of $357,557.

Who is Adam Schayowitz and What is His Real Role at Zymeworks?

Adam Schayowitz serves as Executive Vice President (EVP) and Head of Research & Development (R&D) at Zymeworks. As EVP, he is part of the executive team that sets the company's global strategy, oversees major budgets, and participates in resource allocation decisions. In his R&D role, he leads all scientific activities, including molecule design, preclinical trial conduct, and production team coordination.

This position grants him direct access to confidential information regarding ongoing projects, test results, regulatory deadlines, and commercialization prospects. Such data is considered "material non-public information" under U.S. securities laws, as it could significantly impact the stock's value if made public.

Transaction Details: 13,832 Shares at $25.85 USD Each

The SEC Form 4 filing indicates that the sale involved exactly 13,832 Zymeworks shares, each sold at $25.85 USD. The trade execution date was October 11, 2026, aligning with the two-day mandatory filing period following the transaction.

The total transaction amount is calculated by multiplying the number of shares by the per-unit price, resulting in $357,557 USD. It's important to distinguish between the per-share price ($25.85) and the aggregate value ($357,557), two distinct figures presented in the filing.

Why Insiders Sell Their Shares – Possible Reasons

Executives may choose to liquidate a portion of their holdings to diversify their investments. Holding a significant percentage of a single company's shares exposes the portfolio to concentration risk, and selling reduces this effect while maintaining residual exposure.

Tax planning is also a common motivator. By selling shares when the price is favorable, insiders can realize capital gains subject to taxation while benefiting from deferral or offset mechanisms under applicable laws.

Personal liquidity needs, such as funding real estate projects or covering significant expenses, may justify share sales. This motivation doesn't imply any judgment on the stock's future valuation.

Lastly, the sale may reflect internal insights into potential overvaluation or uncertainty around a specific project. However, no definitive conclusion can be drawn from this single transaction, as motivations are diverse and often private.

How Individual Investors Track Form 4 Filings

The Form 4 is available on the SEC EDGAR platform, accessible online at no cost. Investors can search using ZYME's ticker or Schayowitz's name to view the original document, such as the provided URL: https://www.sec.gov/Archives/edgar/data/2127119/000212711926000006/0002127119-26-000006-index.htm.

Aggregators like OpenInsider, WhaleWisdom, or Bloomberg's tracking modules automatically extract Form 4 data and present it in filterable tables. These tools help quickly identify insider buys or sales, analyze transaction sizes, and track a director's portfolio over time.

It's important to note that Form 4 filings only include the declared transaction details and provide no insight into exact motivations or undisclosed internal projects. Investors should integrate this information into a broader analysis, including financial results, press releases, and sector outlooks.